F&P Healthcare surpasses $1b 1H revenue for the first time
Analysts say it was a robust first-half result from the NZX’s largest company, and one that was hard to pick holes in.
FPH does around 55% of its manufacturing, and all of its R&D, in New Zealand.
NZX- and ASX-listed medical device company Fisher & Paykel Healthcare (FPH) has delivered over $1 billion in first-half revenue for the first time.
It reported a 14% increase in revenue to $1.089 billion for the six months ending September 2025 and a 39% rise in net profit after tax to $213
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
